Senti Biosciences (SNTI) Chardan's 8th Annual Genetic Medicines Conference summary

Company overview and technology platform

• Focuses on gene circuit engineering to enhance control, specificity, and efficacy in cell and gene therapies, especially for oncology.

• Pipeline includes internal cell therapy programs and partnerships in non-oncology areas.

• Technology enables multi-target recognition, addressing the lack of clean, single cancer targets.

• Logic gate approach (NOT gate) protects healthy cells while targeting cancer cells.

• Platform is applicable across cell types, including T cells and NK cells, and for both hematologic and solid tumors.

SENTI-202 program and clinical development

• SENTI-202 is an allogeneic CAR NK cell therapy targeting CD33 and FLT3 for relapsed/refractory AML.

• Uses gene circuit technology to avoid off-tumor toxicity by recognizing endomucin on healthy cells.

• Preclinical data showed eradication of AML in patient-derived models and protection of healthy stem cells.

• Phase I trial underway in the US and Australia, with dosing at days 0, 7, and 14, and response assessed at 28 days.

• Endpoints include safety, PK/PD, efficacy, MRD status, and correlative studies on healthy cell protection.

Upcoming milestones and data readouts

• Initial clinical data from the first patient cohort expected by year-end, focusing on response depth and MRD negativity.

• Higher dose cohorts and durability data anticipated next year.

• Potential expansion into MDS, pediatric AML, and newly diagnosed AML populations.

• Discussions with FDA for pivotal study possible if durable responses are observed.